European Academy of Dermatology and Venereology (EADV) Congress 2024

Treating adolescents with moderate-to-severe AD with the JAK1-selective inhibitor abrocitinib has demonstrated an acceptable long-term safety profile and maintained efficacy for up to 112 weeks, as shown in an adolescent-focused post hoc analysis of 5 phase III trials

Individuals with psoriasis creeping into their intimate areas may find relief from apremilast, as shown by the week-32 improvements in multiple disease parameters in the phase III DISCREET study.

Interim data from the real-world TRACE study confirm the benefits of the high-affinity monoclonal antibody tralokinumab for individuals with moderate-to-severe head and neck atopic dermatitis (H&N AD) after up to 9 months of treatment.

Narrowband ultraviolet B (NB-UVB) phototherapy or light therapy performed at home is as good as one done in the doctor’s office in patients with plaque and guttate psoriasis, as shown in the randomized Light Treatment Effectiveness (LITE) trial presented at EADV 2024.

In the treatment of moderate-to-severe psoriasis, patients with overweight or obesity appear to have a diminished response to vunakizumab compared with those who have lower BMIs, according to a post hoc subgroup analysis of a phase III trial.

A recent study has shown the safety and efficacy of AK 101 (ebdarokimab) in the treatment of patients with plaque psoriasis, achieving ≥75-percent improvement in Psoriasis Area and Severity Index (PASI 75) and Static Physicians Global Assessment (sPGA) 0/1 response.